followers view all
following view all
|healthcarenutrition is not in any groups|
Cancer of the colon and rectum: cure exists,
The number of patients with cancer of the colon and rectum increases. In the European Union each year has detected 260,000 new patients in Slovenia, more than 1100 new cases per year. Unfortunately, the disease most frequently detected in a more advanced stage. However, for patients with cancer of the colon and rectum in this stage of the disease hope,
because there are several types of treatment with cytostatics and in the last year, in combination with its targets (biological) agents.
Cancer of the colon and rectum (colorectal cancer) is in the Western world, the second most common cause of death among all cancer diseases. In the first place is still in women breast cancer in men is lung cancer.
The essential feature of cancer is the uncontrolled cell division that no longer work in accordance with complex physical mechanisms.
Neoplasms occur, which starts deprivation space of healthy cells and destroys tissue. Up to one to two millimeters in diameter does not need its own blood vessels, which could supply nutrients and oxygen. http://www.sarticles.net/article/the-characteristic-signs-of-vitiligo
Such neoplasms, consisting of approximately one million cancer cells, may be stopped, but it can multiply the cell forward.
If the increases needed to live our own veins. Cancerous cells begin to secrete a molecule growth factor for the vasculature to travel to blood vessels in the area and promote their sprouting towards the tumor.
Veins gradually outgrow the tumor and allow him to supply further growth. Tumor, overgrown with its own veins, growing very fast, crawling in the neighborhood (metastasizes), and it soon becomes evident. However, vasculature, served by not properly diversified and has properties
that are characteristic of healthy blood vessels. In many cases, inadequate vascularisation of the tumor guilty of bleeding from the gut, which are often the first sign of cancer of the colon and rectum. http://www.thefreearticles.com/article/procedures-to-cure-vitiligo
Colon Cancer of the colon and rectum in the Western world, the second most common cause of death among malignancy, since it detected most frequently in a more advanced stage. But with new ways of treatment with cytostatics in combination with biologics, are therefore all the more hope for a cure.
Decades, experts searching for a way to disable the tumor supply of nutrients and oxygen through blood vessels and thus interrupt its growth. In 1983, they discovered a molecule (vascular endothelial growth factor, named by VEGF), which plays a key role in the growth of the vascular system, has been developed as an antibody molecule boil. The arrival of a new drug
The first target (bio-) medicine, who started using it to treat cancer of the colon and rectum, cetuximab (Erbitux - Merck),
used to be the second-line treatment with chemotherapy, the disease after the first treatment with chemotherapy again progresses.
It is used to bind to the receptor for the epidermal growth factor receptor or HER 1, which is in fact a protein on the cell surface and is involved in the process of growth and survival of cancer cells.
It does this by blocking the protein. In addition, epidermal growth factor, promoter of the division of cancer cells, is in the development of cancer is also crucial vasculature supplying the tumor with nutrients and oxygen. Neutralization of the molecule
, which is responsible for the growth of cancer cells and the vascular system with the inhibition of tumor growth, however, allows the medicine to bevacizumab (Avastin - Hoffmann-La Roche). Used to be in the first-line treatment, ie in patients with advanced cancer of the colon and rectum, which have not been treated with chemotherapy for advanced disease. Treatment should be used in combination with chemotherapy
Last year also marked the arrival of Slovenia bevacizumab, which extended survival by an average of 30 percent.
By oncologists in the United States may be used for the treatment of February 2004, the countries of the European Union since the beginning of last year, when approved by the European
Agency for the Evaluation of Medicinal Products. In this way the product is registered in Slovenia. Although it is already available for standard therapy is not available.
In the context of widespread availability, bevacizumab was started to use in conjunction with chemotherapy in December 2004. Oncologist Dr. Sarah Ocvirk, dr. between.
spec. internistka, the Institute of Oncology in Ljubljana, says that until last October in patients with treatment-new Target in combination with chemotherapy only in the context of clinical trials and expanded access program, as means to standard therapy have yet to be provided. Treatment option is therefore
dependent on the adoption of additional funding for the introduction of new biological drugs, which have been discussed by the Health Council already last June. Discussed the proposals Institute of Oncology and Medical Centre for the introduction of cancer treatment with biologics.
He suggested treatment for up to 30 patients for each drug. The proposal was sent to the Minister of Health.
|share||like 4||report||64 views|